.

Deeper Knowledge, Faster

  • Anticipate your formulary budget
  • Identify first generic entrants
  • Drug patents and clinical trials in dozens of countries

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Express Scripts
Queensland Health
Novartis
QuintilesIMS
Teva
Julphar
McKesson
Accenture

Generated: June 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,089,534

« Back to Dashboard

Which drugs does patent 9,089,534 protect, and when does it expire?


Patent 9,089,534 protects ABSORICA and is included in one NDA. There have been two Paragraph IV challenges on Absorica.

This patent has ten patent family members in eight countries.

Summary for Patent: 9,089,534

Title:Pharmaceutical semi-solid composition of isotretinoin
Abstract: An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e. having an HLB value superior or equal to 10), the other being an oily vehicle.
Inventor(s): Vanderbist; Francis (Rhode-Saint-Genese, BE), Servais; Cecile (Mehaigne, BE), Baudier; Philippe (Brussels, BE)
Assignee: Galephar Pharmaceutical Research, Inc. (Puerto Rico 00777, unknown)
Application Number:13/713,897
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Ranbaxy
ABSORICA
isotretinoin
CAPSULE;ORAL021951-001May 25, 2012BXRXYesNo9,089,534► SubscribeY
Ranbaxy
ABSORICA
isotretinoin
CAPSULE;ORAL021951-002May 25, 2012BXRXYesNo9,089,534► SubscribeY
Ranbaxy
ABSORICA
isotretinoin
CAPSULE;ORAL021951-005Aug 15, 2014RXYesNo9,089,534► SubscribeY
Ranbaxy
ABSORICA
isotretinoin
CAPSULE;ORAL021951-003May 25, 2012BXRXYesNo9,089,534► SubscribeY
Ranbaxy
ABSORICA
isotretinoin
CAPSULE;ORAL021951-006Aug 15, 2014RXYesNo9,089,534► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 9,089,534

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,078,925Pharmaceutical semi-solid composition of isotretinoin► Subscribe
7,435,427Pharmaceutical semi-solid composition of isotretinoin► Subscribe
8,952,064Pharmaceutical semi-solid composition of isotretinoin► Subscribe
8,367,102Pharmaceutical semi-solid composition of isotretinoin► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,089,534

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2423170► Subscribe
Canada2836228► Subscribe
Germany60104206► Subscribe
European Patent Office1318791► Subscribe
European Patent Office2964195► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Queensland Health
McKinsey
QuintilesIMS
Colorcon
Boehringer Ingelheim
Cipla
Cantor Fitzgerald
Argus Health
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot